Case Report Volume 15 Issue 11 - 2026

Efficacy of Long-Term Use of Histamine Antagonists and Mast Cell Membrane Stabilizers in a Patient with Bronchial Asthma. Clinical Case

Gladkov SF1,2* and Perevoshchikova NK2

1Allergologist-Immunologist: “Clinic of Allergology and Immunology”, Assistant of the Department of Polyclinic Pediatrics, Propaedeutics of Pediatric Diseases and Postgraduate Training “Kemerovo State Medical University” of the Ministry of Health of Russia, Yurga, Russia 2Doctor of Medical Sciences, Professor, Head of the Department of Polyclinic Pediatrics, Propaedeutics of Pediatric Diseases and Postgraduate Training “Kemerovo State Medical University”, Ministry of Health of Russia, Kemerovo, Russia

*Corresponding Author: Gladkov SF, Allergologist-Immunologist: “Clinic of Allergology and Immunology”, Assistant of the Department of Polyclinic Pediatrics, Propaedeutics of Pediatric Diseases and Postgraduate Training “Kemerovo State Medical University” of the Ministry of Health of Russia, Yurga, Russian Federation.
Received: October 27, 2026; Published: November 10, 2026



Introduction: The unfavorable trend of an increase in newly diagnosed cases of bronchial asthma (BA) in childhood is a cause for serious concern. As a rule, the atopic form of BA results from the implementation of the atopic march, for which, unfortunately, there are currently no management options.

Aim: To describe the effectiveness of long-term use of histamine antagonists and mast cell membrane stabilizers in a patient with the atopic form of BA.

Case Presentation: A clinical case is presented concerning the long-term use of cetirizine and ketotifen in the treatment of a patient with bronchial asthma, which demonstrated high efficacy. Comprehensive examination allowed for the verification of the diagnosis: (ICD-10) Bronchial asthma, atopic, moderate, controlled course (J45). Seasonal allergic rhinitis (J30). Food allergy, gastrointestinal form (allergic gastroenteritis/colitis), associated with sensitization to chicken and pork meat (K52.2). Intestinal dysbiosis, stage II, associated with UPM (Staphylococcus aureus - 105 CFU/g, Klebsiella pneumoniae - 106 CFU/g, Klebsiella oxytoca - 105 CFU/g).

Results: Considering the severity of the disease and the lack of effect from basic therapy, the patient was offered a therapeutic course of cetirizine at a dose of 10 mg once daily for up to 30 days and ketotifen 0.5 mg twice daily for up to 30 days, alternately over a period of 18 months. A multidisciplinary approach to therapy made it possible to achieve long-term clinical and laboratory remission with no respiratory symptoms up to the present time (20 years).

Conclusion: The use of a long-term course of a second-generation H1-histamine receptor blocker - cetirizine - and a mast cell membrane stabilizer with moderate H1-histamine blocking activity - ketotifen - in children with the atopic form of asthma is quite reasonable and justified in cases where inhaled glucocorticosteroids prove ineffective.

Keywords: Bronchial Asthma; Cetirizine; Ketotifen; Bacteriophages; Eosinophils; Atopy

Abbreviations: BA: Bronchial Asthma; ECP: Eosinophil Cationic Protein; IgE: Immunoglobulin E; ARVI: Acute Respiratory Viral Infections; EOS: Eosinophils; BOS: Broncho-Obstructive Syndrome; ICD-10: International Classification of Diseases, 10th Revision

  1. Alska E., et al. “Global burden of allergies: mechanisms of development, challenges in diagnosis, and treatment”. Life6 (2025): 878. 
  2. Global Initiative for Asthma. “Global strategy for asthma management and prevention (2025 update)” (2025). 
  3. Kurbacheva OM., et al. “Current aspects of allergen-specific immunotherapy in patients with bronchial asthma: a review of GINA 2024 updates and EfficAPSI study results”. Russian Journal of Allergology2 (2025): 195-206.
  4. Venkatesan P. “2025 GINA report for asthma”. The Lancet Respiratory Medicine 13 (2025): e42. 
  5. Savin IA., et al. “Bronchial asthma, airway remodeling, and lung fibrosis as consecutive stages of a single process”. International Journal of Molecular Sciences22 (2023): 16042. 
  6. Alvarez CA., et al. “Acute and chronic lung inflammation drives changes in epithelial glycans”. Frontiers in Immunology 14 (2023): 1167908. 
  7. Wang X., et al. “Association between exposure to greenness and atopic march in children and adults—a systematic review and meta-analysis”. Frontiers in Public Health 10 (2023): 1097486. 
  8. Byalovsky YY., et al. “Pathogenetic aspects of bronchial asthma phenotyping”. P. Pavlov Russian Medical Biological Herald 32.1 (2024): 145-158. 
  9. Prilutsky AS., et al. “Eosinophils in health and disease. Structure, mediators, development”. Allergology and Immunology in Pediatrics 1 (2023): 5-15.
  10. Kay AB., et al. “The role for eosinophils in airway remodelling in asthma”. Trends in Immunology9 (2004): 477-482. 
  11. Iwata A., et al. “Group 2 innate lymphoid cells in human asthma”. Allergology International2 (2023): 194-200. 
  12. Dong X., et al. “Involvement and therapeutic implications of airway epithelial barrier dysfunction in type 2 inflammation of asthma”. Chinese Medical Journal5 (2022): 519-531. 
  13. Denisova AR., et al. “Verification of diagnosis and routing of children with bronchial asthma using modern capabilities of information systems”. Russian Journal of Allergology4 (2023): 512-520.
  14. Skorokhodkina OV., et al. “Cytokines as biomarkers of eosinophilic inflammation in the T2-endotype of bronchial asthma”. The Bulletin of Contemporary Clinical Medicine6 (2021): 68-75. 
  15. Ministry of Health of the Russian Federation. “Clinical guidelines: bronchial asthma” (2024). 
  16. Diepgen TL and Early Treatment of the Atopic Child Study Group. “Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months”. Pediatric Allergy and Immunology4 (2002): 278-286. 
  17. Kondyurina EG., et al. “Cetirizine in pediatric practice”. Russian Medical Journal 2 (2013): 63.
  18. Zhou P., et al. “Cetirizine for the treatment of allergic diseases in children: a systematic review and meta-analysis”. Frontiers in Pediatrics 10 (2022): 940213. 
  19. “Use of cetirizine and levocetirizine in patients with chronic urticaria and other allergic dermatoses: issues of dose escalation and duration of use. Resolution of the expert council”. Effective Pharmacotherapy25 (2022): 6-14. 
  20. Schwarzer G., et al. “Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children”. Cochrane Database of Systematic Reviews1 (2004): CD001384. 

Gladkov SF and Perevoshchikova NK. “Efficacy of Long-Term Use of Histamine Antagonists and Mast Cell Membrane Stabilizers in a Patient with Bronchial Asthma. Clinical Case”. EC Paediatrics 15.11 (2026): 01-07.